We spoke with James Lanthier, CEO and Joseph Araujo Chief Scientific Officer of Mindset Pharma to discuss their latest breakthrough drug MSP-104 – a psilocybin-based compound about to enter the final preclinical development step prior to commencing first-in-human clinical trials. We further discussed the key differences between MSP-104 as a new generational compared to psilocybin, the current psychedelic landscape, new opportunities and Mindset Pharma’s strategy this year.
Mindset Pharma is a drug discovery business focused on creating novel and patentable psychedelic compounds for the treatment of neurological and psychiatric disorders. The company is assembling a proprietary library of transformative psychedelic intellectual property designed to address chronic neuropsychiatric disorders efficiently and safely.
source